| Literature DB >> 33390886 |
Yongji Zhou1, Yanxing Chen2, Congcong Xu3, Hao Zhang1, Caixiu Lin1.
Abstract
Alzheimer disease (AD) is a devastating neurodegenerative disorder characterized by extracellular accumulation of amyloid-beta and formation of intracellular neurofibrillary tangles. Microglia activation and neuroinflammation play important roles in the pathogenesis of AD; Toll-like receptor 4 (TLR4)-a key component of the innate immune system-in microglia is also thought to be involved based on the observed association between TLR gene polymorphisms and AD risk. TLR4 has been shown to exert both detrimental and beneficial effects on AD-related pathologies. In preclinical models, experimental manipulations targeting TLR4 were shown to improve learning and memory, which was related to inhibition of pro-inflammatory cytokine release and reduction of oxidative stress. In this review, we summarize the key evidence supporting TLR4 as a promising therapeutic target in AD treatment.Entities:
Keywords: Alzheimer’s disease; microglia; neuroinflammation; therapeutic target; toll-like receptor 4
Year: 2020 PMID: 33390886 PMCID: PMC7775514 DOI: 10.3389/fnins.2020.602508
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677